|
Anjiang (AJ) Liu, Ph.D., MBA, Associate Banker. Prior to joining Aurora, Dr. Liu worked in equity research for Syntax Institutional Research, a Rochester, NY based independent equity research firm. He was responsible for building financial valuation models and covering small cap biotech and pharmaceutical companies. Dr. Liu also worked for Trillium Group, a Rochester, New York, based venture capital firm. At Trillium, he helped raising private equity investment for OyaGen Inc, a biopharmaceutical start-up company focused on developing a novel class of anti-HIV drug based on its RNA and DNA editing enzyme technology. In 2002, he co-founded Weiheng Biotech in China and served as Director of Research. Dr. Liu received his medical degree from the Medical School of Xi’an Jiaotong University (formerly Xi’an Medical University) in China, his Ph.D. degree from Drexel University and his MBA degree from Simon Graduate School of Business Administration, University of Rochester. Dr. Liu holds the following securities industry registrations: (i) registered representative (Series 7), (ii) state agent (Series 63). | 